CompletedPhase 1/2

Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

China130 participantsStarted 2023-10-01

Plain-language summary

This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1.Adults 18-80 years old 2.ASA :I-III 3.Patients who are able to give informed consent and are currently planning to have the lesion removed or examined at the descending ERCP Exclusion Criteria:1: Use of anticholinergic drugs 2: pregnancy 3: glaucoma 4: Myasthenia gravis 5: Obstructive gastrointestinal diseases 6: Obstructive urinary tract disease (prostatic hyperplasia) 7: Heart disease (coronary heart disease, congestive heart failure) 8: hyperthyroidism 9: Previous history of abdominal or intestinal surgery 10: Chronic renal failure \-

What they're measuring

Incidence of postoperative nausea and vomiting

Timeframe: Timepoint：24 hours after the ERCP

Trial details

NCT IDNCT06045364

SponsorJie Chen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-20

View on ClinicalTrials.gov More Nausea and Vomiting trials